MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596704 | Name: Etoricoxib HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Etoricoxib HCl is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.

Chemical Structure

Etoricoxib HCl
Etoricoxib HCl
CAS#202409-40-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 596704

Name: Etoricoxib HCl

CAS#: 202409-40-3 (HCl)

Chemical Formula: C18H16Cl2N2O2S

Exact Mass: 0.0000

Molecular Weight: 395.29

Elemental Analysis: C, 54.69; H, 4.08; Cl, 17.94; N, 7.09; O, 8.09; S, 8.11

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
202409-40-3 (HCl) 202409-33-4 (free base)
Synonym
Etoricoxib hydrochloride; Etoricoxib HCl; L-791456 HCl; L 791456 HCl; L791456 HCl;
IUPAC/Chemical Name
5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-2,3'-bipyridine hydrochloride
InChi Key
NNGHGPAKTWAHHB-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H15ClN2O2S.ClH/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23;/h3-11H,1-2H3;1H
SMILES Code
O=S(C1=CC=C(C2=CC(Cl)=CN=C2C3=CC=C(C)N=C3)C=C1)(C)=O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 395.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Clarke R, Derry S, Moore RA. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2014 May 8;5:CD004309. doi: 10.1002/14651858.CD004309.pub4. Review. PubMed PMID: 24809657. 2: Lories RJ. Etoricoxib and the treatment of ankylosing spondylitis. Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1599-608. doi: 10.1517/17425255.2012.741120. Epub 2012 Nov 6. Review. PubMed PMID: 23126318. 3: Clarke R, Derry S, Moore RA. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2012 Apr 18;4:CD004309. doi: 10.1002/14651858.CD004309.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;5:CD004309. PubMed PMID: 22513922. 4: Alekseeva LI. [Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program)]. Ter Arkh. 2010;82(8):57-62. Review. Russian. PubMed PMID: 20873248. 5: Croom KF, Siddiqui MA. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Drugs. 2009 Jul 30;69(11):1513-32. doi: 10.2165/00003495-200969110-00008. Review. PubMed PMID: 19634927. 6: Clarke R, Derry S, Moore RA, McQuay HJ. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004309. doi: 10.1002/14651858.CD004309.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD004309. PubMed PMID: 19370600. 7: Chilet-Rosell E, Ruiz-Cantero MT, Horga JF. Women's health and gender-based clinical trials on etoricoxib: methodological gender bias. J Public Health (Oxf). 2009 Sep;31(3):434-45. doi: 10.1093/pubmed/fdp024. Epub 2009 Mar 14. Review. PubMed PMID: 19287020. 8: Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20. Review. PubMed PMID: 18840026. 9: Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review. PubMed PMID: 18405470. 10: Yuan Y, Hunt RH. Global gastrointestinal safety profile of etoricoxib and lumiracoxib. Curr Pharm Des. 2007;13(22):2237-47. Review. PubMed PMID: 17691997. 11: Capone ML, Tacconelli S, Patrignani P. Clinical pharmacology of etoricoxib. Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):269-82. Review. PubMed PMID: 16922642. 12: Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J. 2005 Oct 7;118(1223):U1684. Review. PubMed PMID: 16224508. 13: Martina SD, Vesta KS, Ripley TL. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005 May;39(5):854-62. Epub 2005 Apr 12. Review. PubMed PMID: 15827069. 14: Matsumoto AK, Cavanaugh PF Jr. Etoricoxib. Drugs Today (Barc). 2004 May;40(5):395-414. Review. PubMed PMID: 15319795. 15: Leclercq P, Malaise MG. [Etoricoxib (Arcoxia)]. Rev Med Liege. 2004 May;59(5):345-9. Review. French. PubMed PMID: 15270001. 16: Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother. 2003 Feb;4(2):265-84. Review. PubMed PMID: 12562317. 17: Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs. 2002;62(18):2637-51; discussion 2652-3. Review. PubMed PMID: 12466002.